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Abstract
Aspergilloma and invasive aspergillosis coexisting with multidrug resistant Mycobacterium
tuberculosis (MDR-TB) in the same patient is a rare entity. We report a 50 year old South Indian
woman, a diabetic, who presented to us with complaints of productive cough and hemoptysis for
the past 2 months. She was diagnosed to have pulmonary tuberculosis 2 years ago for which she
took irregular treatment. Lung imaging showed features of a thick walled cavity in the right upper
lobe with an indwelling aspergilloma. She underwent a right lung upper lobe resection. Biopsy and
culture of the resected specimen showed the coexistence of Aspergillus fumigatus and multi-drug
resistant Mycobacterium tuberculosis. 2 blood cultures grew Aspergillus fumigatus. She was
successfully treated with Voriconazole and anti tuberculous therapy against MDR-TB.
Background
Pulmonary tuberculosis is the most commonly associated
disease in cases of secondary aspergilloma [1]. Generally
aspergilloma is seen residing in an old tuberculous cavity.
In this case report we present a rare case of an aspergil-
loma co-existing with multidrug resistant mycobacterium
tuberculous in an old cavity. This patient also had invasive
aspergillosis. This combination is uncommon and to the
best of our knowledge is not reported in literature.
Case presentation
A 50 year old South Indian woman presented to the out-
patient department of our tertiary care hospital with com-
plaints of productive cough with hemoptysis for the past
2 months. She was a house wife and was from a low socio
economic class. She was diagnosed to have pulmonary
tuberculosis 2 years ago and was started on anti-tubercu-
lous therapy consisting of Isoniazid (300 mg), Rifampicin
(600 mg), Ethambutol (1200 mg), and Pyrazinamide
(1500 mg). But within just 3 weeks she had discontinued
treatment on her own. She suffered from diabetes mellitus
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with peripheral neuropathy for the past 8 years and was
taking oral hypoglycemic agents for the same. There was
no history of hypothyroidism, coronary artery disease,
hepatic disease or renal disease. No history of relevant
family diagnosis of parents, siblings, or children was elic-
ited. She is not a known smoker or alcoholic. She is mar-
ried and currently postmenopausal for past 5 years. She
weighed 53 kgs and was 156 cms tall with a body mass
index was 22 kg/m2. General physical examination was
unremarkable. Respiratory system exam revealed bron-
chial breath sounds in the right infraclavicular area.
Admission baseline investigations showed anemia. Renal
and liver functions were within normal limits (Table 1).
Computed tomogram of the thorax revealed a thick
walled cavity in the right lung upper lobe with an indwell-
ing aspergilloma (Figure 1). 3 sputum samples were tested
positive for acid fast bacilli by Ziehl Neelsen's staining
technique. Conventional method of culture on Lowen-
stein Jensen's medium yielded growth of M. tuberculosis
in 6 weeks time. The anti-tuberculosis drug susceptibility
performed by resistance ratio method using Lowenstein
Jensen's medium showed resistance to Isoniazid,
Rifampicin but sensitive to Ethambutol, Pyrazinamide
and Streptomycin in their critical concentrations of 2 ug,
50 ug and 4 ug respectively as given by Lee and Heifet.8.
Consequently in view of hemoptysis and presence of an
aspergilloma a right upper lobectomy was performed
(after anemia correction with 3 units of packed red cell
transfusion). Biopsy of the resected specimen showed
caseous necrosis and granuloma formation (Figure 2) and
septate fungal elements suggestive of Aspergillus species
(Figure 3). A fungal culture of the resected specimen in
Sabouraud's dextrose agar grew 'dirty green colonies', with
lactophenol cotton blue slide mount showed fungal ele-
ments characteristic of Aspergillus fumigatus. 2 Blood cul-
ture inoculated in Sabouraud's dextrose agar also grew
Aspergillus fumigatus. In view of invasive Aspergillosis
patient was given an oral loading dose of Voriconazole
400 mg 12th hourly for 2 doses which was followed by an
oral maintenance dose of 200 mg 12th hourly was contin-
ued for 6 weeks. Initially before AFB culture reports were
ready, the patient was initiated empirically on a daily dose
of Isoniazid (300 mg), Ethambutol (1200 mg), Pyrazina-
mide (1500 mg) and Streptomycin 1 g. Rifampicin due to
Computed tomogram of the thorax Figure 1
Computed tomogram of the thorax. Thick walled cavity 
in the right lung upper lobe with an indwelling aspergilloma.
Caseating granuloma suggestive of Tubercular infection Figure 2
Caseating granuloma suggestive of Tubercular infec-
tion. Histology picture showing Langhan's giant cells, epith-
eloid cells with surrounding necrosis (H and E × 100).
Aspergillus species Figure 3
Aspergillus species. Histology picture showing fungal 
hyphae of Aspergillus (Periodic Acid Schiff-G stain × 400).Cases Journal 2008, 1:303 http://www.casesjournal.com/content/1/1/303
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its interactions with Voriconazole was not included in the
treatment regimen [2]. After culture demonstrated MDR-
TB, Isoniazid was stopped and oral Levofloxacin 750 mg
once a day and Ethionamide 250 mg 12th hourly were
included as per WHO protocol for MDR-TB [3]. Hemopt-
ysis completely resolved after lobectomy. Within a week
of initiating Voriconazole blood became sterile for fungal
elements. After 3 weeks sputum became negative for acid
fast bacilli. Currently patient is in the 4th month of treat-
ment and is doing well.
Discussion
TB is principally a disease of poverty, with 95% of cases
and 98% of deaths occurring in developing countries. Of
these, more than half the cases occur in five South-East
Asian countries [4]. Globally, about 3% of all newly diag-
nosed patients have MDR-TB [5]. Definition of multi-drug
resistance refers to isolates resistant to both Isoniazid and
Rifampicin with or without resistance to other drugs [5].
Three common forms of pulmonary disease associated
with Aspergillus infection has been described, namely,
allergic aspergillosis, colonizing aspergillosis, and inva-
sive aspergillosis. A study showed that aspergilloma was
commonly associated with pulmonary tuberculosis and
affected the upper lobes in 94% of the cases [6]. Our
patient also had pulmonary tuberculosis and aspergil-
loma had affected the right upper lobe. The uniqueness of
our case report is that this association between MDR-TB,
aspergilloma and invasive aspergillosis in the same
patient is rare and to the best of our knowledge has not
been reported in the literature before.
The natural history of aspergilloma is variable. Hemopty-
sis is the commonest mode of presentation, with an inci-
dence of around 80%, which is life threatening in 30%
[7]. In the majority of cases, the lesion remains stable,
however, in approximately 10% of cases, it may decrease
in size or resolve spontaneously without treatment [8].
Rarely, the aspergilloma increases in size [9]. Predicted
mortality due to aspergilloma is reported at a rate of 6%
per annum [10]. Surgery not only offers symptomatic con-
trol but also confers survival advantage [11]. Hemoptysis
completely resolved in our patient after right lung upper
lobe resection. Invasive aspergillosis is commonly seen in
immunocompromised patients. Except for the poorly
controlled diabetes, we could not identify any other risk
factor for invasive fungal infection in our patient.
Conclusion
Aspergilloma, invasive aspergillosis, and MDR-TB can
coexist in the same patient. Hence patients who have a
recurrence of tuberculosis, and who were previous
defaulters of antitubercular therapy, an AFB culture
should be performed in order to identify MDR-TB. Sur-
gery often gives good results in the treatment of aspergil-
loma. Systemic antifungals should be administered
against invasive fungal infections.
Patient's perspective
I have realized my mistake of stopping the TB medicines.
Now the treatment is prolonged and the injection is pain-
ful. I could have spread these resistant bacteria to many
people. Hence forth I will be careful and follow my doc-
tor's instructions. I have learnt my lesson for sure but in a
hard way.
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Table 1: Laboratory investigations
Hemoglobin 7 g/dl
Total count 4,500 cells/mm3
Differential count Poly morphs: 73%
Lymphocytes: 24%
Eosinophils: 3%
Platelet count 3,25,000 cells/mm3
Serum creatinine 0.9 mg/dl
Total serum bilirubin 1.1 mg/dl
Direct bilirubin 0.6 mg/dl
Random blood sugar 231 mg/dl
ELISA for HIV 1 and 2 non – reactive
Sputum AFB (3 samples) Positive
Sputum culture Mycobacterium tuberculosis (MDR-TB)
Blood culture (2 samples) Aspergillus fumigatusPublish with BioMed Central    and   every 
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